Amplia Therapeutics ASX:ATX will partner with US drug maker Eli Lilly & Company on a Phase 1b/2b clinical trial to assess the combination of Amplia’s investigational focal adhesion kinase (FAK) inhibitor narmafotinib with Eli Lilly’s investigational KRAS G12C inhibitor olomorasib.The companies have…
Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ASX:ATX, OTCQB:INNMF, (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026.Amplia Board chair Ms Jane…
Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ASX:ATX, OTCQB:INNMF, (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan.Dr. Tong said, “It is a great privilege to serve on the Amplia Board and to help shape the Bo…
Amplia Therapeutics Ltd ASX:ATX:
